证券代码：000952 证券简称：广济药业 公告编号：2023-04 3 湖北广济药业股份有限公司 关于参加 2023 年湖北辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： ●会议召开时间：2023 年 5 月 25 日（星期四）14:30-16:35 ●会议召开地点：全景路演（http://rs.p5w.net）网络平台 ●会议召开方式：网络文字互动 一、说明会类型 为进一步加强湖北广济药业股份有限公司（以下简称"公司"）与投资者互 动交流，根据湖北省上市公司协会《关于举办 2023 年湖北辖区上市公司投资者 网上集体接待日活动的通知》（鄂上协发〔2023〕15 号），公司将于 2023 年 5 月 25 日下午参加由中国证券监督管理委员会湖北监管局、湖北省上市公司协会、 深圳市全景网络有限公司联合举办的"2023 年湖北辖区上市公司投资者网上集 体接待日活动"，通过网络与投资者互动交流。 二、活动召开的时间、方式 召开时间：2023 年 5 月 25 日（星期四）14:30-16:35 会议方式 ...

湖北广济药业股份有限公司投资者关系活动记录表 证券代码：000952 证券简称：广济药业 编号：2023-002 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访  业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称及 | 通过中国证券报·中证网（http://www.cs.com.cn/roadshow/yjsmh/） | | 人员姓名 | 参与公司 2022 年度网上业绩说明会的广大投资者 | | 时 间 | 2023 年 5 月 12 日 15:00-16:30 | | 地 点 | 武汉市光谷企业天地二号楼二楼会议室 | | 上市公司接待人 | 董事长：阮澍先生 财务总监：胡明峰先生 | | 员姓名 | 董事会秘书：郑彬先生 独立董事：梅建明先生 | | | 一、公司董事长致辞 | | | 尊敬的各位领导、投资者朋友们： | | | 大家下午好！欢迎大家参加湖北广济药业股份有限公司在中国证券报 | | | 中证网举办的 2022 年度业绩说明会。首先我代表公司全体员工对广大投资 | | | ...

证券代码：000952 证券简称：广济药业 公告编号：2023—038 湖北广济药业股份有限公司 关于举办 2022 年度网上业绩说明会并征集问题的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 湖北广济药业股份有限公司（以下简称"公司"）于 2023 年 4 月 20 日披露 2022 年年度报告及摘要，为加强与投资者交流，使投资者更加全面、深入地了 解公司经营情况，公司拟通过网络方式举办 2022 年度业绩说明会，欢迎广大投 资者积极参与。 一、网上业绩说明会的安排 1、召开时间：2023 年 5 月 12 日（星期五）【15:00--16:30】 本次业绩说明会召开后，投资者可以通过中证网路演中心查看本次业绩说明 会的召开情况及主要内容。 3、参与方式：本次年度业绩说明会将采用网络方式举行，投资者可登录中 国证券报·中证网（https://www.cs.com.cn/roadshow/yjsmh/）参与 2022 年度 网上业绩说明会。 二、征集问题事项 为充分尊重投资者、提升交流的针对性，使广大投资者更深入、全面地了解 公司 2022 年年度经营 ...

Financial Performance - The company's revenue for Q1 2023 was ¥115,290,588.81, a decrease of 13.49% compared to ¥133,271,899.34 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥44,038,541.85, representing a decline of 627.02% from a profit of ¥8,356,171.56 in the previous year[5] - Basic earnings per share were -¥0.1244, down 611.93% from ¥0.0243 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 115,290,588.81, a decrease of 13.5% compared to CNY 133,271,899.34 in Q1 2022[25] - Operating profit for Q1 2023 was a loss of CNY 45,298,268.91, compared to a profit of CNY 8,728,468.35 in Q1 2022[25] - The total profit for Q1 2023 was a loss of ¥45,818,121.92, compared to a profit of ¥7,709,901.39 in the same period last year[26] - The net profit for Q1 2023 was a loss of ¥45,398,332.51, while the previous year reported a net profit of ¥7,655,581.24[26] - The total comprehensive income for Q1 2023 was a loss of ¥45,395,595.80, while the previous year reported a comprehensive income of ¥7,647,988.93[26] Cash Flow - The net cash flow from operating activities was -¥63,018,293.69, a significant decrease of 19,051.47% compared to -¥329,051.98 in the same period last year[11] - The cash flow from operating activities showed a net outflow of ¥63,018,293.69, compared to a minor outflow of ¥329,051.98 in the previous year[29] - Cash inflow from sales of goods and services was ¥144,688,065.30, down from ¥153,321,440.76 in the same period last year[28] - The company reported a cash and cash equivalents balance of ¥389,386,320.35 at the end of Q1 2023, down from ¥428,782,094.47 at the beginning of the period[30] - The company incurred total cash outflows from investing activities of ¥32,887,188.75, compared to ¥56,998,496.47 in the previous year[29] - The financing activities generated a net cash inflow of ¥56,711,572.15, down from ¥162,240,812.11 in the same period last year[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,459,551,578.44, a slight decrease of 0.38% from ¥2,469,053,947.84 at the end of the previous year[5] - Current liabilities rose to CNY 767,897,890.29, an increase of 17.4% compared to CNY 654,034,226.07 at the start of the year[23] - Total liabilities increased to CNY 1,009,183,586.25 from CNY 977,247,826.66, reflecting a growth of 3.3%[23] - Non-current assets totaled CNY 1,478,713,003.29, up from CNY 1,463,558,529.70, indicating a growth of 1.7%[22] - The company's retained earnings decreased to CNY 600,543,239.78 from CNY 644,581,781.63, a decline of 6.8%[23] Expenses - Research and development expenses increased by 78.90% to ¥16,432,520.06, primarily due to costs associated with vitamin B2 process research and other pharmaceutical product developments[10] - The company reported a significant increase in sales expenses, which rose by 106.17% to ¥9,763,244.33, mainly due to market research and advertising costs[10] - Total operating costs increased to CNY 160,483,094.07, up 19.4% from CNY 134,378,996.03 in the previous year[25] Investments and Financing - Short-term borrowings increased by 36.46% to ¥269,000,000.00, driven by the need for production and operational financing[8] - The net cash flow from financing activities decreased by 65.04% to ¥56,711,572.15, primarily due to a reduction in bank loans obtained during the reporting period[12] - The company plans to establish a joint venture with Jining Yanzhou District Huimin Urban Investment Co., holding 90% of the joint venture, with a registered capital of RMB 520 million[16] - The total price for the restructuring transaction involving four companies is RMB 520 million, with the company bearing 90% of the cost, amounting to RMB 468 million[16] - The company has approved a borrowing limit of RMB 200 million from its controlling shareholder, with a loan term of 3 years at an interest rate of 4.8%[18] - The company plans to engage in financing leasing with a total financing amount of RMB 140 million for production equipment over a 3-year lease term[18] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 30,659[14] - The largest shareholder, Changjiang Industrial Investment Group, holds 24.75% of the shares, totaling 87,592,065 shares[14] - The company’s controlling shareholder had 37,539,103 shares released from restrictions on April 18, 2023[19] Subsidiaries and Corrections - The company has established a wholly-owned subsidiary, Hubei Guanghua Pharmaceutical Co., to serve as a chemical synthesis base[20] - The company corrected prior accounting errors, impacting the consolidated profit and loss statement for 2022 and 2021, but not affecting the balance sheet or cash flow statement[19] - The company has completed the registration of its wholly-owned subsidiary and obtained the business license from the local authority[20]

Financial Performance - The company's revenue for Q1 2022 was CNY 133,271,899.34, a decrease of 24.42% compared to CNY 176,325,538.59 in the same period last year[4] - Net profit attributable to shareholders was CNY 8,356,171.56, down 39.62% from CNY 13,838,265.84 year-on-year[4] - Total operating revenue for Q1 2022 was CNY 133,271,899.34, a decrease of 24.4% compared to CNY 176,325,538.59 in the same period last year[22] - Net profit for Q1 2022 was CNY 7,655,581.24, a decline of 40.5% from CNY 12,935,440.72 in Q1 2021[24] - The company's operating profit for Q1 2022 was CNY 8,728,468.35, down 51.2% from CNY 17,897,295.19 in the previous year[23] - The company's basic earnings per share decreased by 56.29% to CNY 0.0243 from CNY 0.0556 in the same period last year[4] - Earnings per share for Q1 2022 were CNY 0.0243, compared to CNY 0.0556 in Q1 2021[24] Cash Flow - The net cash flow from operating activities was negative at CNY -329,051.98, a decline of 101.15% compared to CNY 28,496,950.04 in the previous year[4] - Cash flow from operating activities in Q1 2022 was CNY -329,051.98, a significant decrease from CNY 28,496,950.04 in Q1 2021[26] - The total cash inflow from operating activities was CNY 167,905,381.54, compared to CNY 171,384,340.33 in the same period last year[26] - The net cash flow from investment activities was -46,697,286.75, compared to -23,944,091.49 in the previous year, indicating a significant increase in cash outflow[27] - The total cash inflow from financing activities was 334,443,480.00, up from 102,651,520.00 in the same period last year, reflecting a strong financing effort[27] - The net cash flow from financing activities was 162,240,812.11, compared to -28,468,667.35 in the previous year, showing a positive turnaround[27] - The cash and cash equivalents increased by 115,115,827.44, contrasting with a decrease of -23,814,552.10 in the previous year[27] - The total cash and cash equivalents at the end of the period amounted to 318,188,097.11, compared to 265,723,641.72 at the end of the previous year[27] - The company received cash from borrowings amounting to 275,000,000.00, compared to 102,651,520.00 in the previous year, indicating increased leverage[27] Assets and Liabilities - Total assets increased by 13.06% to CNY 2,316,525,859.76 from CNY 2,048,896,426.54 at the end of the previous year[4] - The total liabilities as of March 31, 2022, were CNY 1,047,438,850.65, compared to CNY 739,955,538.71 at the beginning of the year, reflecting an increase of approximately 41.6%[19] - Total liabilities as of Q1 2022 amounted to CNY 858,073,922.87, an increase from CNY 598,092,478.58 in the previous year[23] - The company's long-term borrowings rose dramatically by 521.04% to CNY 213,950,000.00, reflecting increased financing needs for operations[8] - The company's cash and cash equivalents increased to CNY 405,484,067.73 from CNY 293,332,160.43, representing a growth of about 38.2%[18] - Accounts receivable rose to CNY 193,938,139.72 from CNY 182,981,957.15, indicating an increase of approximately 6.4%[18] - The company's long-term equity investments increased to CNY 38,738,693.52 from CNY 32,513,867.21, showing a growth of about 19.1%[19] Inventory and Expenses - The company’s inventory increased by 32.49% to CNY 218,384,674.56, attributed to higher procurement of pharmaceutical distribution and trading[8] - Total operating costs for Q1 2022 were CNY 134,378,996.03, down 15.5% from CNY 158,967,357.47 in Q1 2021[23] - The company reported a significant increase in financial expenses by 59.45% to CNY 4,666,459.58 due to increased borrowing[10] - The company reported a decrease in research and development expenses to CNY 9,185,119.75 from CNY 7,506,265.22 in the previous year, indicating a 22.4% increase[23] - The company spent 46,998,496.47 on the acquisition of fixed assets, intangible assets, and other long-term assets, compared to 24,183,491.49 in the previous year, indicating increased capital expenditure[27] Strategic Initiatives - The company plans to implement a mixed reform strategy by introducing a research and development team to enhance its capabilities in drug formulation and production[16] - Hubei Guangji Pharmaceutical has established a subsidiary, Hubei Guangji Pharmaceutical Technology Co., Ltd., to strengthen its R&D efforts, which was registered in March 2022[16] - The company has approved a restricted stock incentive plan, granting 8.649 million shares at a price of CNY 3.52 per share to 118 eligible participants[14] Reporting and Audit - The company did not undergo an audit for the first quarter report[28] - The report was published by the board of directors on April 27, 2022[29]

Financial Performance - The company's revenue for Q3 2022 was ¥160,264,829.93, representing a 4.73% increase year-over-year, while the year-to-date revenue reached ¥536,281,129.73, up 12.59% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was a loss of ¥4,788,962.79, a decrease of 133.11% year-over-year, and the year-to-date net profit was ¥19,907,205.68, down 73.16% compared to the previous year[5] - Total operating revenue for the third quarter reached ¥536,281,129.73, an increase of 12.6% compared to ¥476,334,358.27 in the same period last year[24] - Net profit for the quarter was ¥18,272,970.78, a decrease of 74.2% from ¥70,762,725.31 in the previous year[25] - The total comprehensive income for Q3 2022 was CNY 18,261,637.36, a decrease from CNY 70,728,188.49 in the same period last year[26] - The net profit attributable to the parent company was CNY 19,895,872.26, down from CNY 74,148,944.93 year-on-year[26] - Basic earnings per share for Q3 2022 were CNY 0.0564, compared to CNY 0.2156 in Q3 2021[26] Expenses and Costs - The company reported a significant increase in R&D expenses, which rose by 77.99% to ¥51,573,922.12, primarily due to investments in optimizing the fermentation process for Vitamin B2 and other pharmaceutical formulation projects[8] - Total operating costs amounted to ¥528,709,910.51, up 26.2% from ¥419,085,867.85 year-on-year[24] - The company’s sales expenses increased by 49.22% to ¥23,252,236.24, driven by expanded marketing channels and increased advertising costs[8] - The company reported a decrease in investment income of 73.72%, amounting to ¥4,942,171.01, due to significant fluctuations in profits from its associate company[8] Assets and Liabilities - Total assets as of September 30, 2022, were ¥2,351,308,234.63, reflecting a 14.76% increase from the end of the previous year[5] - Current assets totaled ¥919,980,790.18, a rise of 29.6% from ¥708,955,538.71 at the start of the year[21] - The company’s total liabilities increased to ¥893,136,460.65, compared to ¥598,092,478.58 in the previous year[22] - Long-term borrowings rose significantly to ¥252,855,000.00 from ¥34,450,000.00 year-on-year[22] - The equity attributable to shareholders of the parent company was ¥1,468,476,833.80, slightly up from ¥1,462,474,772.88 year-on-year[22] Cash Flow - The company experienced a 100.85% decline in net cash flow from operating activities, resulting in a negative cash flow of ¥598,622.65 for the year-to-date period[9] - Cash inflow from operating activities was CNY 642,729,723.94, an increase from CNY 507,761,446.92 in the previous year[27] - Cash flow from investing activities resulted in a net outflow of CNY 59,583,541.99, compared to a net outflow of CNY 39,001,358.06 in the previous year[28] - Cash flow from financing activities generated a net inflow of CNY 207,913,854.07, recovering from a net outflow of CNY -7,966,789.63 in the same period last year[28] - The ending cash and cash equivalents balance was CNY 352,866,514.95, up from CNY 312,683,285.79 at the end of the previous year[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,674[11] - The largest shareholder, Changjiang Industrial Investment Group Co., Ltd., holds 24.84% of the shares, totaling 87,592,065 shares[11] - The top ten shareholders hold a total of 50,052,962 unrestricted shares, representing a significant portion of the company's equity[11] - The company has not identified any related party relationships among its top ten shareholders, except for Changjiang Industrial Investment Group Co., Ltd.[12] Strategic Initiatives - The company plans to implement a "mixed reform" strategy to enhance its R&D capabilities by establishing a subsidiary with Wuhan Tongtai Qixin Enterprise Management Consulting Partnership[15] - A capital increase of RMB 45 million was approved for its wholly-owned subsidiary, Hubei Guangji Pharmaceutical Jikang Pharmaceutical Co., Ltd., to support its diversification strategy[18] - The company has completed the registration of its subsidiary, Hubei Guangji Pharmaceutical Technology Co., Ltd., to strengthen its product development platform[15] - The company has signed an agreement to acquire state-owned land use rights totaling 154.63 acres for RMB 56,473,404.54[18] - The company provided a guarantee for its subsidiary's transaction with a maximum amount of RMB 120 million for equipment leasing[17]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 376,016,299.80, representing a 16.30% increase compared to CNY 323,308,914.09 in the same period last year[21]. - The net profit attributable to shareholders decreased by 58.65% to CNY 24,696,168.47 from CNY 59,719,564.69 year-on-year[21]. - Basic earnings per share dropped by 59.50% to CNY 0.0703 from CNY 0.1736 in the same period last year[21]. - The net profit after deducting non-recurring gains and losses fell by 60.55% to CNY 13,086,836.87 from CNY 33,173,669.00 year-on-year[21]. - The company's operating revenue for the reporting period was ¥376,016,299.80, representing a year-on-year increase of 16.30% due to growth in pharmaceutical distribution and sales[43]. - The total operating revenue for the first half of 2022 was CNY 376,016,299.80, representing an increase of 16.3% compared to CNY 323,308,914.09 in the same period of 2021[157]. - The net profit for the first half of 2022 was CNY 23,237,487.61, a decrease of 59.9% from CNY 57,855,880.23 in the previous year[158]. - The gross profit margin for the pharmaceutical manufacturing sector was 38.58%, a decrease of 0.50% compared to the previous year[48]. - The gross profit margin for the first half of 2022 was reported at 4.4%, down from 18.5% in the same period of 2021[158]. Cash Flow and Liquidity - The net cash flow from operating activities turned negative at CNY -14,598,814.46, a decline of 130.53% compared to CNY 47,812,008.22 in the previous year[21]. - The company's cash and cash equivalents decreased by ¥29,374,639.51, a decline of 123.58% year-on-year, due to increased payments for goods and services and debt repayments[44]. - The company reported a total cash and cash equivalents balance of ¥173.70 million at the end of the first half of 2022, down from ¥414.14 million at the end of the first half of 2021[165]. - The cash outflow for debt repayment was 303,845,000.00 CNY, which increased from 182,815,000.00 CNY, indicating a rise of approximately 66.1%[167]. - The net increase in cash and cash equivalents for the period was -2,388,804.06 CNY, contrasting with an increase of 111,383,222.59 CNY in the previous period[167]. Investment and R&D - Research and development investment rose by 57.76% to ¥29,323,266.68, reflecting increased spending on optimizing fermentation processes and developing new pharmaceutical formulations[44]. - The company completed 3 patent applications in the first half of 2022, bringing the total number of domestic and international patents to 90, including 33 invention patents[40]. - The company plans to increase its investment in its subsidiary Jikang Company to 50 million yuan to enhance its pharmaceutical commercial platform's core competitiveness and profitability[35]. - The company is focusing on the integration of "raw materials + formulations" to accelerate the development of its pharmaceutical formulation business[34]. - The company is investing in environmental protection measures, which will increase operational costs, to comply with stricter regulations on energy conservation and emissions[68]. Market and Sales Performance - The sales revenue from the pharmaceutical distribution and agency business reached 55.92 million yuan, showing a significant year-on-year increase of 302.79%[35]. - Revenue from the pharmaceutical manufacturing sector was ¥320,091,847.81, accounting for 85.13% of total revenue, with a year-on-year growth of 3.45%[46]. - Domestic revenue increased by 44.04% to ¥263,265,033.59, while international revenue decreased by 19.77% to ¥112,751,266.21[46]. - The company has initiated a new distribution business model to expand sales channels and customer resources, which is expected to support future product development[48]. Assets and Liabilities - Total assets increased by 7.96% to CNY 2,211,898,530.61 from CNY 2,048,896,426.54 at the end of the previous year[21]. - Total liabilities as of June 30, 2022, were CNY 751,875,122.23, up from CNY 598,092,478.58, representing an increase of about 25.66%[151]. - The company's equity attributable to shareholders increased to CNY 1,470,152,914.16 from CNY 1,462,474,772.88, showing a slight growth of approximately 0.05%[151]. Corporate Governance and Management - The company’s management structure is robust, with ongoing improvements in governance and a long-term incentive plan to align management goals with business objectives[41]. - The company emphasizes transparency and communication with shareholders, enhancing information disclosure and investor protection measures[94]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[104]. Environmental Responsibility - The company has established a robust environmental management system, with all pollution control facilities operating normally and no instances of exceeding emission standards reported[80]. - The company’s wastewater discharge for ammonia nitrogen was reported at 93.54 mg/l, well below the standard of 35 mg/l, indicating effective pollution control measures[78]. - The company has obtained various environmental approvals for its projects, including a modern upgrade of the Vitamin B2 production facility and a wastewater utilization project[81][83]. Future Outlook and Strategy - The company plans to expand its market presence by investing in new product development and enhancing its technological capabilities[174]. - The company has set a performance guidance for the second half of 2022, aiming for a revenue growth of 15% to 20%[173]. - The company aims to establish a high-quality product development platform to address its current deficiencies in formulation R&D capabilities[124].

Financial Performance - The company's operating revenue for 2022 was ¥797,642,746, a decrease of 1.54% compared to ¥837,106,649 in 2021[21] - The net profit attributable to shareholders for 2022 was ¥50,366,243, representing a significant decline of 54.26% from ¥110,107,173 in the previous year[21] - The net cash flow from operating activities decreased by 40.61% to ¥45,079,614 in 2022, down from ¥75,907,303 in 2021[21] - Basic earnings per share fell by 55.20% to ¥0.1434 in 2022, compared to ¥0.3201 in 2021[21] - Total assets at the end of 2022 increased by 20.51% to ¥2,469,053,947, up from ¥2,048,896,426 at the end of 2021[21] - The net assets attributable to shareholders increased by 2.75% to ¥1,502,636,584 at the end of 2022, compared to ¥1,462,474,777 at the end of 2021[21] - The weighted average return on net assets decreased to 3.40% in 2022 from 7.78% in 2021, indicating a decline in profitability[21] - The company reported a total of CNY 20.91 million in non-recurring gains in 2022, a decrease from CNY 44.47 million in 2021[28] Revenue Breakdown - In 2022, the company's total revenue for the four quarters was approximately CNY 133.27 million, CNY 242.74 million, CNY 160.26 million, and CNY 261.36 million respectively[25] - The net profit attributable to shareholders for the four quarters was CNY 8.36 million, CNY 16.34 million, -CNY 4.79 million, and CNY 30.46 million respectively[25] - The net profit after deducting non-recurring gains and losses for the four quarters was -CNY 3.32 million, CNY 16.41 million, -CNY 6.23 million, and CNY 22.60 million respectively[25] - Revenue from the pharmaceutical manufacturing sector decreased by 2.12% to ¥682,183,152.55, accounting for 85.52% of total revenue[55] - Domestic revenue increased by 21.06% to ¥580,843,269.58, while international revenue decreased by 29.10% to ¥216,799,476.49[56] Operational Challenges - In 2022, the company faced a decline in sales volume for high-content vitamin B2 and 80% feed-grade vitamin B2 due to increased competition and weak terminal demand, leading to a decrease in sales revenue and net profit[39] - The overall gross margin for the pharmaceutical manufacturing sector is under pressure due to rising raw material costs, necessitating strategic adjustments[62] - The company has experienced an increase in operating expenses due to the implementation of a restricted stock incentive plan for 147 employees, impacting overall profitability[39] Research and Development - The company has established a comprehensive R&D system focusing on biotechnological applications, optimizing fermentation processes, and expanding product categories in the vitamin B family[37] - Research and development expenses increased by 32.49% to 68.98 million yuan, focusing on optimizing fermentation processes and developing new pharmaceutical formulations[49] - The company completed 3 patent applications in the first half of 2022, with a total of 90 domestic and international patents authorized, including 33 invention patents[45] - The company plans to enhance its product pipeline in three key areas: pharmaceutical raw materials, high-value nutritional additives, and bio-based materials[93] Strategic Initiatives - The company is positioned to benefit from regulatory changes in the pharmaceutical sales sector, which will enhance compliance and oversight[33] - The company has invested 50 million yuan to enhance the core competitiveness and profitability of its wholly-owned subsidiary, Jikang Company, in the pharmaceutical commercial platform[41] - The company signed a strategic cooperation framework agreement with Beijing Blue Crystal Microbiology for industrial cooperation in new food materials and new materials[50] - The company is conducting due diligence on the acquisition of Shandong Baisheng Biotechnology Co., Ltd., which will enhance its product offerings and market competitiveness[51] Governance and Compliance - The company maintains complete independence from its controlling shareholder in business, personnel, assets, and finance[107] - The company has established a sound governance structure, ensuring the protection of stakeholders' rights and interests[104] - The company adheres to strict information disclosure regulations, ensuring all shareholders have equal access to information[105] - The company has established environmental protection measures and obtained pollution discharge permits valid until December 2025[155] Environmental and Social Responsibility - The company has improved its governance system and enhanced information disclosure management to protect the rights of shareholders and investors[162] - The company has engaged in various activities to facilitate communication with small and medium investors, including online performance briefings and investor reception days[162] - The company is committed to fulfilling its social responsibilities, contributing to community stability and development[165] - The company has implemented a diverse welfare system for employees, including regular health check-ups and cultural activities[164] Future Outlook - The company plans to enhance its market expansion strategies and is focusing on new product development and technological advancements[116] - The company aims for a revenue growth target of 20% for 2023, driven by both existing and new product lines[129] - New product launches are expected to contribute an additional 200 million CNY in revenue in 2023, with a focus on innovative drug formulations[129] - The company plans to continue enhancing its R&D capabilities by attracting high-quality young talent to support its growth strategy[69]

Financial Performance - The company's operating revenue for 2021 was ¥785,573,171.02, representing a 14.15% increase compared to ¥688,169,323.69 in 2020[19] - The net profit attributable to shareholders for 2021 was ¥110,107,173.86, a significant increase of 47.50% from ¥74,647,103.88 in 2020[19] - The net profit after deducting non-recurring gains and losses was ¥65,639,729.59, which is a 69.85% increase from ¥38,645,048.49 in 2020[19] - The basic earnings per share for 2021 was ¥0.3201, up 43.41% from ¥0.2232 in 2020[19] - The total operating revenue for 2021 was ¥785,573,171.02, representing a year-on-year increase of 14.15% compared to ¥688,169,323.69 in 2020[50] - The net profit attributable to shareholders reached 110.11 million yuan, reflecting a significant growth of 47.50% compared to the previous year[42] - The total operating costs increased by 18.55% year-on-year, reaching 484,327,988 CNY, primarily due to the growth in pharmaceutical distribution and raw material production and sales[59] Assets and Cash Flow - The total assets at the end of 2021 were ¥2,048,896,426.54, reflecting a 3.51% increase from ¥1,979,438,635.76 at the end of 2020[20] - The net cash flow from operating activities decreased by 36.42% to ¥75,907,303.46 in 2021 from ¥119,381,525.89 in 2020[19] - The company's cash and cash equivalents decreased by ¥86,465,924.15 in 2021, a decline of 181.66% compared to an increase of ¥105,885,637.27 in 2020[71] - The proportion of accounts receivable increased to 8.93% of total assets in 2021, up from 5.26% in 2020, primarily due to new receivables from a major client[77] Research and Development - The company completed 23 patent applications in 2021, including 5 invention patents and 18 utility model patents, enhancing its R&D capabilities[42] - The R&D expenses increased by 34.28% to 52.06 million yuan, driven by investments in optimizing fermentation processes for vitamin B2 and stable production strains[43] - The number of R&D personnel rose to 203 in 2021, a 3.57% increase from 196 in 2020, with a notable increase in the number of bachelor's degree holders by 31.82%[68] - The company is actively developing multiple products in its R&D pipeline, indicating a focus on innovation and market responsiveness[99] Market and Industry Position - The company is a major global supplier of Vitamin B2, benefiting from national policies that encourage high-quality development in the raw material pharmaceutical industry[30] - The pharmaceutical industry is experiencing intensified competition due to reforms in the medical system and policies promoting centralized procurement, impacting pricing strategies[28] - The vitamin market is characterized by cyclical price fluctuations, with significant impacts from supply and demand dynamics since 2007[32] - The company aims to leverage its advantages in raw materials and technology to adapt to new economic conditions and enhance its market position[30] Corporate Governance - The company maintains a robust corporate governance structure, ensuring compliance with relevant laws and regulations, and protecting shareholder rights[103] - The board of directors consists of 9 members, including 3 independent directors, ensuring a diverse and compliant governance framework[104] - The company has established effective communication channels with investors, enhancing transparency and engagement[105] - The company has a clear ownership of assets and operates independently without any asset or fund occupation by the controlling shareholder[107] Environmental Responsibility - The company emphasizes sustainable development through green and energy-saving processes, reducing pollution and waste during production[39] - The company is classified as a key pollutant discharge unit, with specific emissions data reported for wastewater and air pollutants[159] - The average COD concentration for wastewater discharge was reported at 91.05 mg/L, with a total discharge of 48.2 tons[159] - The company has established various board committees, including the audit committee and strategic management committee, to enhance governance practices[156] Employee Management - The total number of employees at the end of the reporting period was 1,317, with 786 in production, 62 in sales, 207 in technical roles, 27 in finance, and 235 in administration[138] - The company has a training plan in place to enhance employee skills and knowledge, aiming for a win-win situation for both the company and its employees[141] - The company has a structured employee compensation scheme that includes basic salary, monthly performance, annual performance, and benefits, closely linking performance to company results[140] - The company emphasizes employee career development and has established a fair platform for professional growth[171] Strategic Initiatives - The company plans to distribute a cash dividend of ¥0.60 per 10 shares, based on a total of 343,999,939 shares[4] - The company is focusing on expanding its market presence and enhancing its product offerings through new strategies and technologies[116] - The company is actively pursuing opportunities for mergers and acquisitions to enhance its competitive position in the market[116] - The company has implemented a restricted stock incentive plan in 2021 to attract and retain key management personnel, enhancing team cohesion and competitiveness[156]